Corrigendum

Corrigendum to “Production of Long-Acting CNGRC-CPG2 Fusion Proteins: New Derivatives to Overcome Drug Immunogenicity of Ligand Directed Enzyme Prodrug Therapy for Targeted Cancer Treatment.”

Al-mansoori L, Al Qahtani AD, Elsinga P, Goda SK. Production of Long-Acting CNGRC–CPG2 Fusion Proteins: New Derivatives to Overcome Drug Immunogenicity of Ligand-Directed Enzyme Prodrug Therapy for Targeted Cancer Treatment. Technology in Cancer Research & Treatment. January 2021. doi:10.1177/15330338211057371

The authors missed adding an acknowledgement in the article prior to publication. The authors contacted the editorial office and requested that an additional acknowledgement be added.

In this article, the current Acknowledgement reads as “The authors thank Fatma Rashidi for carrying out some technical work including the CD spectral.”

The corrected Acknowledgement is provided below:

Acknowledgment The authors thank Fatma Rashidi for carrying out some technical work including the CD spectral. The authors would like to thank Barzan Holdings for their funding of the open access publication fees.